Medicine Distribution Consents




11 JUNE NEW ZEALAND GAZETTE 1755

Consent to the Distribution of a New Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Lamivudine 150 mg Tablet, film coated Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom 3TC
Lamivudine 10 mg/mL Solution, oral Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom 3TC
Aspirin 25 mg, dipyridamole 200 mg Capsule, modified release Boehringer Ingelheim Pharma KG., Biberach an der Riss, Germany and Boehringer Ingelheim Pharma KG., Ingelheim am Rhein, Germany Asasantin Retard
Clotrimazole 1%, 2% Cream, vaginal Taro Pharmaceuticals Inc., Bramelea, Ontario, Canada Clotrimaderm
Clotrimazole 1% Cream, topical Taro Pharmaceuticals Inc., Bramelea, Ontario, Canada Clotrimazole
Felodipine 5 mg, metoprolol succinate 47.5 mg equivalent to 50 mg metoprolol tartrate; felodipine 10 mg, metoprolol succinate 95 mg equivalent to 100 mg metoprolol tartrate Tablets, modified release Astra Pharmaceutical Production AB., Södertälje, Sweden Logimax
Fluvoxamine maleate 50 mg, 100 mg Tablets, film coated Solvay Duphar BV., Olst, The Netherlands Luvox
Vinorelbine tartrate 13.85 mg/mL equivalent to 10 mg/mL vinorelbine Injection, solution Aquitaine Pharm International, Pierre Fabre Medicament Subsidiary, Idron, France Navelbine
Grepafloxacin hydrochloride sesquihydrate 236.4 mg equivalent to 200 mg grepafloxacin Tablet, film coated Otsuka Pharmaceutical Co Limited, Tokushima-shi, Tokushima, Japan Raxar
Grepafloxacin hydrochloride sesquihydrate 472.8 mg, 709.2 mg equivalent to 400 mg, 600 mg grepafloxacin Tablets, film coated Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom Raxar
Salbutamol sulphate 60 µg/dose equivalent to 50 µg/dose salbutamol Inhalation powder Astra Pharmaceutical Production AB., Södertälje, Sweden Salbutamol Turbuhaler
Topiramate 25 mg, 50 mg, 100 mg, 200 mg, 300 mg Tablet, film coated Janssen-Cilag Farmaceutica LDA., Queluz de Baixo, Queluz, Portugal Topamax
Daclizumab 5mg/mL Infusion, concentrate Hoffmann-La Roche Inc., Nutley, New Jersey, United States of America Zenapax
Zolmitriptan 2.5 mg, 5 mg Tablets, film coated IPR Pharmaceuticals Inc., Carolina, San Juan, Puerto Rico Zomig

Dated this 5th day of June 1998.

G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.

g04012

Consent to the Distribution of Changed Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Sulphamethoxazole 40 mg/mL, trimethoprim 8 mg/mL Suspension, oral Novex Pharma Inc., Richmond Hill, Ontario, Canada Apo-Sulfatrim
Ciprofloxacin hydrochloride 0.35% equivalent to 0.3% ciprofloxacin Drops, eye, solution S A Alcon Couvreur NV., Puurs, Belgium Ciloxan


Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1998, No 79


NZLII PDF NZ Gazette 1998, No 79





✨ LLM interpretation of page content

🏥 Consent to the Distribution of a New Medicine

🏥 Health & Social Welfare
5 June 1998
Medicines, Distribution, Consent, New Medicine, Schedule
  • G. R. BOYD, Chief Advisor, Regulation and Safety

🏥 Consent to the Distribution of Changed Medicines

🏥 Health & Social Welfare
Medicines, Distribution, Consent, Changed Medicine, Schedule